Novel Inhibitors of DNA Ligase LigA by Substrate-Assisted Tethered Inhibition
通过底物辅助束缚抑制的 DNA 连接酶 LigA 新型抑制剂
基本信息
- 批准号:9089917
- 负责人:
- 金额:$ 21.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-01 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acinetobacter baumanniiAffinityAmino Acyl-tRNA SynthetasesAnti-Bacterial AgentsAntibiotic ResistanceAntibioticsBindingBiological AssayDNA LigasesDataDevelopmentDrug TargetingDrug resistanceEnterobacterEnzyme Inhibitor DrugsEnzyme InhibitorsEnzyme KineticsEnzymesEscherichia coliGlycolsGram-Negative BacteriaGrowthIn VitroInfectionKlebsiella pneumonia bacteriumLibrariesMetabolicModelingOutcomePathway interactionsPharmaceutical PreparationsPhasePropertyPseudomonas aeruginosaReactionResistanceResistance profileRiboseSpecificityStructure-Activity RelationshipTherapeuticThigh structureTimeTranslationsX-Ray Crystallographyadductantimicrobialdesignefflux pumpimprovedin vivoinhibitor/antagonistinnovationleucine-tRNAmutantnovelnovel therapeuticspathogenpre-clinicalpublic health relevanceresidenceresistance frequencyresistance mechanismresistance mutationsmall molecule
项目摘要
DESCRIPTION (provided by applicant): Novel therapeutics are needed to treat infections caused by antibiotic-resistant Gram-negative ESKAPE pathogens. DNA Ligase LigA is a validated target for antibacterial discovery, however the translation of LigA competitive inhibitor has been hindered by the rapid emergence of resistance mutations. We will use an innovative substrate-assisted tethered inhibition strategy to develop potent inhibitors of LigA that form a covalent adduct with enzyme-intermediate(s) on the reaction pathway. These inhibitors will thus be uncompetitive with NAD+, circumventing a major mechanism of resistance. We will also seek to identify inhibitors that have long residence times on the enzyme. This will result in increased target suppression at low drug concentration thereby reducing the emergence of resistance while simultaneously improving the therapeutic window of the compounds. In the R21 phase of the proposal, we will synthesize a focused library of oxaboroles (~100-150) guided by our initial modeling and determine the ability of these compounds to inhibit the LigA from K. pneumonia, A. baumannii P. aeruginosa, and E. coli. We will determine MICs against wild-type and efflux-pump mutants of each pathogen (Aim 1). We will develop structure-activity relationships for LigA inhibition using enzyme kinetics, X-ray crystallography and computational approaches (Aim 2) to inform additional compound synthesis. The objective of this aim will be to identify non/uncompetitive inhibitors with IC50 < 1 µM Kd < 0.1 µM (for E-AMP binding) and MIC < 8 µg/ml against efflux-pump strains. In the R33 phase we will focus our efforts on pathogen(s) that demonstrated the greatest sensitivity to the LigA inhibitors in the R21 phase and synthesize additional compounds with improved antibacterial activity against wild-type strain(s). The objective of the R33 phase is to deliver compound(s) with in vivo efficacy (= 1 log CFU decrease) and suitable properties for further optimization and preclinical development. Activities will include improving microbiological activity against wild-type strains, assessment of resistance
frequency and in vitro and in vivo DMPK.
描述(由申请人提供):需要新型治疗剂来治疗由耐药性革兰氏阴性ESKAPE病原体引起的感染。DNA连接酶LigA是一种有效的抗菌靶标,然而,LigA竞争性抑制剂的翻译受到快速出现的耐药突变的阻碍。我们将使用创新的底物辅助束缚抑制策略来开发强效的LigA抑制剂,使其与反应途径上的酶中间体形成共价加合物。因此,这些抑制剂将与NAD+无竞争力,从而避免了主要的耐药机制。我们还将寻求识别在酶上具有长停留时间的抑制剂。这将导致在低药物浓度下增加的靶标抑制,从而减少耐药性的出现,同时改善化合物的治疗窗口。在该提案的R21阶段,我们将在我们的初始建模指导下合成氧杂硼杂环戊烯(~100-150)的集中库,并确定这些化合物抑制来自K的LigA的能力。pneumonia,A.鲍曼不动杆菌、铜绿假单胞菌和E.杆菌我们将确定针对每种病原体的野生型和外排泵突变体的MIC(目的1)。我们将使用酶动力学,X射线晶体学和计算方法(目的2)开发LigA抑制的结构-活性关系,以告知其他化合物的合成。该目标的目的是鉴定对外排泵菌株具有IC 50 < 1 µM Kd < 0.1 µM(对于E-AMP结合)和MIC < 8 µg/ml的非/非竞争性抑制剂。在R33阶段,我们将集中精力研究在R21阶段对LigA抑制剂表现出最大敏感性的病原体,并合成对野生型菌株具有改善的抗菌活性的其他化合物。R33阶段的目的是递送具有体内功效(= 1 log CFU减少)和合适性质的化合物,用于进一步优化和临床前开发。活动将包括提高对野生型菌株的微生物活性,
频率以及体外和体内DMPK。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER J TONGE其他文献
PETER J TONGE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER J TONGE', 18)}}的其他基金
Mechanism of Slow Onset Enzyme Inhibition and Translation to Time-Dependent Drug Activity
缓慢起效的酶抑制机制及其转化为时间依赖性药物活性
- 批准号:
10623704 - 财政年份:2023
- 资助金额:
$ 21.27万 - 项目类别:
A PET Diagnostic for Imaging Bacterial Infection
细菌感染成像 PET 诊断
- 批准号:
10006663 - 财政年份:2020
- 资助金额:
$ 21.27万 - 项目类别:
Evaluation of a Novel Infection PET Diagnostic
新型感染 PET 诊断的评估
- 批准号:
10020585 - 财政年份:2019
- 资助金额:
$ 21.27万 - 项目类别:
Novel PET Radiotracers for Imaging Infection
用于感染成像的新型 PET 放射性示踪剂
- 批准号:
10165712 - 财政年份:2018
- 资助金额:
$ 21.27万 - 项目类别:
Novel PET Radiotracers for Imaging Infection
用于感染成像的新型 PET 放射性示踪剂
- 批准号:
9768480 - 财政年份:2018
- 资助金额:
$ 21.27万 - 项目类别:
Novel Inhibitors of DNA Ligase LigA by Substrate-Assisted Tethered Inhibition
通过底物辅助束缚抑制的 DNA 连接酶 LigA 新型抑制剂
- 批准号:
8956176 - 财政年份:2015
- 资助金额:
$ 21.27万 - 项目类别:
Mechanism of Slow Onset Enzyme Inhibition and Drug Target Residence Time
缓慢起效的酶抑制机制和药物靶标停留时间
- 批准号:
8545198 - 财政年份:2012
- 资助金额:
$ 21.27万 - 项目类别:
Mechanism of Slow Onset Enzyme Inhibition and Drug Target Residence Time
缓慢起效的酶抑制机制和药物靶标停留时间
- 批准号:
8918683 - 财政年份:2012
- 资助金额:
$ 21.27万 - 项目类别:
Mechanism of Slow Onset Enzyme Inhibition and Drug Target Residence Time
缓慢起效的酶抑制机制和药物靶标停留时间
- 批准号:
8727068 - 财政年份:2012
- 资助金额:
$ 21.27万 - 项目类别:
Mechanism of Slow Onset Enzyme Inhibition and Translation to Time-Dependent Drug Activity
缓慢起效的酶抑制机制及其转化为时间依赖性药物活性
- 批准号:
9896835 - 财政年份:2012
- 资助金额:
$ 21.27万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 21.27万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 21.27万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 21.27万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 21.27万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 21.27万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 21.27万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 21.27万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 21.27万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 21.27万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 21.27万 - 项目类别:
Continuing Grant